ES2032405T3 - Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2032405T3
ES2032405T3 ES198787108550T ES87108550T ES2032405T3 ES 2032405 T3 ES2032405 T3 ES 2032405T3 ES 198787108550 T ES198787108550 T ES 198787108550T ES 87108550 T ES87108550 T ES 87108550T ES 2032405 T3 ES2032405 T3 ES 2032405T3
Authority
ES
Spain
Prior art keywords
valproenoic
valproico
procedures
derivatives
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787108550T
Other languages
English (en)
Inventor
Paolo Chiesi
Vittorino Servadio
Flavio Villani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2032405T3 publication Critical patent/ES2032405T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/40—Vinylene carbonate; Substituted vinylene carbonates

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

SORPRENDENTEMENTE, SE HA DEMOSTRADO QUE LOS ESTERES DEL ACIDO 2-PROPIL-2-PENTENOICO (ACIDO VALPROICO) Y LOS ESTERES DEL ACIDO (E)-2-PROPIL-2-PENTENOICO [ACIDO (E)-2-VALPROENOICO POSEEN VALIOSAS PROPIEDADES, PORQUE MUESTRAN ACTIVIDADES ANTICONVULSIVAS Y ANTIEPILEPTICAS COMPAREBLES A LAS DEL ACIDO VALPROICO, ASI COMO UNA MEJOR BIODISPONIBILIDAD Y UNA TOXICIDAD NOTABLEMENTE REDUCIDA.
ES198787108550T 1986-06-19 1987-06-13 Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2032405T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20846/86A IT1190133B (it) 1986-06-19 1986-06-19 Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche

Publications (1)

Publication Number Publication Date
ES2032405T3 true ES2032405T3 (es) 1993-02-16

Family

ID=11172940

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787108550T Expired - Lifetime ES2032405T3 (es) 1986-06-19 1987-06-13 Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (9)

Country Link
US (1) US5162573A (es)
EP (1) EP0250997B1 (es)
JP (1) JPH07108881B2 (es)
AT (1) ATE74900T1 (es)
CA (1) CA1331186C (es)
DE (1) DE3778219D1 (es)
ES (1) ES2032405T3 (es)
GR (1) GR3004712T3 (es)
IT (1) IT1190133B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627487B1 (fr) * 1988-02-19 1991-03-29 Martin Laboratoires Nouveau derive de l'acide valproique, procede de preparation de ce compose ainsi que medicament antiepileptique le contenant
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
JP2004520263A (ja) 2000-07-21 2004-07-08 テバ　ファーマシューティカル　インダストリーズ　リミティド 双極性障害における躁病を治療するためのバルプロ酸および２−バルプロエン酸アミド誘導体の使用
US6720445B2 (en) * 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
WO2003073988A2 (en) 2002-02-28 2003-09-12 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
EP1549323A2 (en) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
MXPA05005398A (es) * 2002-11-22 2006-03-09 Univ Johns Hopkins Meta para terapia de deterioro cognitivo.
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
JP5917148B2 (ja) 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
CN104797568A (zh) * 2012-05-08 2015-07-22 塞利克斯比奥私人有限公司 用于治疗神经障碍的组合物和方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES403631A1 (es) * 1972-06-08 1975-05-01 Made Labor Sa Un metodo de obtencion de dos esteres de n-(2-hidroxietil)-pirrolidina.
IT1061352B (it) * 1973-03-27 1983-02-28 Crinos Industria Farmaco Sali misti di esteri polisolforici di glicopeptidi naturali con metalli e con basi organiche e procedimento per la loro preparazione
GB1437868A (en) * 1973-05-09 1976-06-03 Synthelabo Arylpiperazinoalkyl esters
FI783743A (fi) * 1977-12-14 1979-06-15 Gerot Pharmazeutika Foerfarande foer framstaellning av 3-di-n-propyl-acetoxi-benzodiazepin-2-oner
IL59407A (en) * 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
IT1121282B (it) * 1979-06-08 1986-04-02 Medea Res Srl Composto ad attivita'antiepilettica e anticonvulsivante,processo per la sua preparazione e composizioni farmaceutiche relative
AT365164B (de) * 1980-06-04 1981-12-28 Lagap S A Pharmaceuticals Verfahren zur herstellung des neuen pivaloyloxymethyl-2-propylpentanoats
IL67623A (en) * 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IT1194343B (it) * 1983-07-26 1988-09-14 Valeas Spa Sali di endo-8,8-dialchil-8-azoniabiciclo (3.2.1) ottan-6,7-esso-epossi-3-alchilcarbossilati,processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPH0713028B2 (ja) * 1986-03-31 1995-02-15 日東電工株式会社 外皮投与用組成物

Also Published As

Publication number Publication date
DE3778219D1 (de) 1992-05-21
IT8620846A0 (it) 1986-06-19
JPH07108881B2 (ja) 1995-11-22
IT1190133B (it) 1988-02-10
JPS6366153A (ja) 1988-03-24
EP0250997A2 (en) 1988-01-07
EP0250997A3 (en) 1988-12-14
EP0250997B1 (en) 1992-04-15
CA1331186C (en) 1994-08-02
US5162573A (en) 1992-11-10
IT8620846A1 (it) 1987-12-19
GR3004712T3 (es) 1993-04-28
ATE74900T1 (de) 1992-05-15

Similar Documents

Publication Publication Date Title
ES2032405T3 (es) Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2059437T3 (es) Un metodo para preparar una composicion.
AR023401A1 (es) Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con restos de azucar, procedimientos para su preparacion, medicamentos que contienen estoscompuestos, y su empleo para preparar un medicamento
AR248139A1 (es) Procedimiento para obtener compuestos del acido 7-acil-3-vinil-3-cefem-4-carboxilico y sus sales.
CR6026A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2130111T3 (es) Derivados de ciclohexano, preparaciones que los contienen y su utilizacion.
ES2052166T3 (es) Derivados de 24-homo-vitamina-d, procedimiento para su preparacion, preparados farmaceuticos que contienen estos derivados asi como su utilizacion como medicamentos.
TNSN87012A1 (fr) Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
MX9300628A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2054738T3 (es) Derivados de acido 3-desmetil-4-fluoromevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su empleo y productos intermedios.
ES2066390T3 (es) Nuevos derivados del espiro-(4.5)-decano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2127263T3 (es) Nuevos trien-derivados cromenicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
FR2429019A1 (fr) Medicaments contenant des esters de 1-b-d-arabinofuranosylcytosine-5'-phosphate
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES532124A0 (es) Un procedimiento para preparar derivados de acido 4, 7-dihidropirazolo (3, 4-b) piridin-5-carboxilico
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES471993A1 (es) Procedimiento de preparacion de nuevos derivados de alcaloi-des pentaciclicos
ES2054904T3 (es) Procedimiento para la preparacion de peptidos con actividad inhibidora de sistemas enzimaticos.
PT82175B (pt) Processo para preparacao de novos derivados de 3-piridilmetilnaftalina e de composicoes farmceuticas que os contem
ES2074984T3 (es) Compuestos de 2-oxa-isocefem, composiciones que los contienen y procedimientos para su preparacion.
ES2090806T3 (es) Acilsulfonamido- y sulfonamido-piridina-2-esteres de acidos carboxilicos, asi como sus piridina-n-oxidos, procedimientos para su preparacion y su utilizacion como medicamentos.
UY24832A1 (es) Nuevos compuestos derivados del benzoperhidroisoindol, útiles como inhibidores de la farnesil transferasa, procedimiento para prepararlos, los intermediarios de sintesis y su preparación, las composiciones farmacéuticas que contienen dichos derivados
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 250997

Country of ref document: ES